CLIPS BnC Inc. (the Company) is a full scope clinical contract research organization (CRO), and a biotechnology company focusing on the development of novel cell therapeutics and vaccines. As a CRO, the company provides comprehensive clinical development services, such as regulatory affairs consulting, medical writing, clinical trial management, and data management & statistics, to biopharmaceutical companies.

The company is actively expanding its business overseas by establishing CLIPS BnC Thailand and a joint venture in China to address the needs of strategic partners in the APAC region. As a biotech, the company is developing a limbal stem cell therapy, which is about to enter the Phase 2 trial, and vaccines for infectious diseases with unmet medical needs, including respiratory syncytial virus (RSV) and methicillin resistant Staphylococcus aureus (MRSA).